Clinical Trial Update: A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of Samelisant (SUVN-G3031) in narcolepsy patients with and without cataplexy has completed and results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy

Drugs mentioned

• Samelisant (SUVN-G3031)

Snippet

Sponsor: Suven Life Sciences Limited | Conditions: Narcolepsy | Phase 2 | Status: COMPLETED | Results posted: 2025-01-13